Antihypertensive treatment and risk of atrial fibrillation: a nationwide study

被引:93
作者
Marott, Sarah C. W. [1 ,3 ]
Nielsen, Sune F. [1 ,3 ]
Benn, Marianne [1 ,2 ,3 ]
Nordestgaard, Borge G. [1 ,3 ]
机构
[1] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark
[2] Gentofte Univ Hosp, Dept Clin Biochem, DK-2900 Hellerup, Denmark
[3] Univ Copenhagen, Copenhagen Univ Hosp, Fac Hlth & Med Sci, DK-2200 Copenhagen N, Denmark
基金
英国医学研究理事会;
关键词
Hypertension; Medication; Primary prevention; Arrhythmia; Stroke; Epidemiology; II RECEPTOR BLOCKADE; ANGIOTENSIN SYSTEM; HEART-FAILURE; PREVENTION; MORTALITY; HYPERTENSION; INHIBITION; MORBIDITY; CANCER; TRIAL;
D O I
10.1093/eurheartj/eht507
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To examine the associations between antihypertensive treatment with angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs), beta-blockers, diuretics, or calcium-antagonists, and risk of atrial fibrillation. We examined these associations using the entire Danish population from 1995 through 2010. Methods and results Excluding medication used in atrial fibrillation, we matched individuals on ACEi monotherapy 1:1 with individuals on beta-blocker (n = 48 658), diuretic (n = 69 630), calcium-antagonist (n = 57 646), and ARB monotherapy (n = 20 158). Likewise, individuals on ARB monotherapy were matched 1:1 with individuals on beta-blocker (n = 20 566), diuretic (n = 20 832), calcium-antagonist (n = 20 232), and ACEi monotherapy (n = 20 158). All were free of atrial fibrillation and of predisposing diseases like heart failure, ischaemic heart disease, diabetes mellitus, and hyperthyroidism at baseline and none received any other antihypertensive medication. We studied risk of atrial fibrillation, and used risk of stroke, influenced by lowering blood pressure rather than renin-angiotensin system blockade per se, as an indicator of the importance of blood pressure lowering per se. Hazard ratios of atrial fibrillation for ACEi and ARB monotherapy were 0.12 (95% CI: 0.10-0.15) and 0.10 (0.07-0.14) compared with beta-blocker, 0.51 (0.44-0.59) and 0.43 (0.32-0.58) compared with diuretic, and 0.97 (0.81-1.16) and 0.78 (0.56-1.08) compared with calcium-antagonist monotherapy. Risk of stroke did not differ among the five antihypertensive medications. Conclusion Use of ACEis and ARBs compared with beta-blockers and diuretics associates with a reduced risk of atrial fibrillation, but not stroke, within the limitations of a retrospective study reporting associations. This suggests that controlling activation of the renin-angiotensin system in addition to controlling blood pressure is associated with a reduced risk of atrial fibrillation.
引用
收藏
页码:1205 / U47
页数:11
相关论文
共 30 条
[1]   Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease [J].
Boldt, A ;
Wetzel, U ;
Welgl, J ;
Garbade, J ;
Lauschkel, J ;
Hindricks, G ;
Kottkamp, H ;
Gummert, JF ;
Dhein, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (10) :1785-1792
[2]   Impact of Hypertension on Stroke [J].
Dubow, Jordan ;
Fink, Matthew E. .
CURRENT ATHEROSCLEROSIS REPORTS, 2011, 13 (04) :298-305
[3]   Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program [J].
Ducharme, Anique ;
Swedberg, Karl ;
Pfeffer, Marc A. ;
Cohen-Solal, Alain ;
Granger, Christopher B. ;
Maggioni, Aldo P. ;
Michelson, Eric L. ;
McMurray, John J. V. ;
Olsson, Lars ;
Rouleau, Jean L. ;
Young, James B. ;
Olofsson, Bertil ;
Puu, Margareta ;
Yusuf, Salim .
AMERICAN HEART JOURNAL, 2006, 152 (01) :86-92
[4]   Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence [J].
Ehrlich, JR ;
Hohnloser, SH ;
Nattel, S .
EUROPEAN HEART JOURNAL, 2006, 27 (05) :512-518
[5]   Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study [J].
Epstein, AE ;
Slabaugh, J ;
Barnard, D ;
Hammitt, L ;
Kaplan, AJ ;
Allen, B ;
Lui, C ;
Aguirre, L ;
Koshkarian, GM ;
Spiegler, K ;
Goldman, S ;
Ohm, J ;
Greer, G ;
Daly, J ;
Bissett, JK ;
Cotter, B ;
Dennish, GW ;
Jones, C ;
Pai, S ;
Bishop, V ;
Browning, R ;
Kotlewski, A ;
Haywood, LJ ;
Pruitt, C ;
Warner, A ;
Machuca, K ;
Behboodikhah, M ;
Delano, S ;
Brodsky, MA ;
Ahmadi-Kashani, M ;
Rubin, AM ;
Fattoruso, L ;
O'Neill, G ;
Skadsen, A ;
Linz, P ;
Kozlowski, J ;
Feld, GK ;
Tone, LM ;
Rapoport, E ;
Somelofski, CA ;
Havranek, EP ;
Smith, I ;
Rosenfeld, LE ;
Vanzetta, AM ;
Hamilton, S ;
Kirmser, R ;
Williams, D ;
Mbonu, ID ;
Gooray, D ;
Shetty, R .
AMERICAN HEART JOURNAL, 2002, 143 (06) :991-1001
[6]   2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2006 WRITING COMMITTEE MEMBERS Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [J].
Fuster, Valentin ;
Ryden, Lars E. ;
Cannom, Davis S. ;
Crijns, Harry J. ;
Curtis, Anne B. ;
Ellenbogen, Kenneth A. ;
Halperin, Jonathan L. ;
Kay, G. Neal ;
Le Huezey, Jean-Yves ;
Lowe, James E. ;
Olsson, S. Bertil ;
Prystowsky, Eric N. ;
Tamargo, Juan Luis ;
Wann, L. Samuel ;
Estes, N. A. Mark, III ;
Ezekowitz, Michael D. ;
Jackman, Warren M. ;
January, Craig T. ;
Page, Richard L. ;
Slotwiner, David J. ;
Stevenson, William G. ;
Tracy, Cynthia M. ;
Jacobs, Alice K. ;
Anderson, Jeffrey L. ;
Albert, Nancy ;
Buller, Christopher E. ;
Creager, Mark A. ;
Ettinger, Steven M. ;
Guyton, Robert A. ;
Hochman, Judith S. ;
Kushner, Frederick G. ;
Ohman, Erik Magnus ;
Tarkington, Lynn G. ;
Yancy, Clyde W. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (11) :E101-E198
[7]   Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial [J].
Goette, Andreas ;
Schoen, Norbert ;
Kirchhof, Paulus ;
Breithardt, Guenter ;
Fetsch, Thomas ;
Haeusler, Karl Georg ;
Klein, Helmut U. ;
Steinbeck, Gerhard ;
Wegscheider, Karl ;
Meinertz, Thomas .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2012, 5 (01) :43-U116
[8]   Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial [J].
Hansson, L ;
Lindholm, LH ;
Niskanen, L ;
Lanke, J ;
Hedner, T ;
Niklason, A ;
Luomanmäki, K ;
Dahlöf, B ;
de Faire, U ;
Mörlin, C ;
Karlberg, BE ;
Wester, PO ;
Björck, JE .
LANCET, 1999, 353 (9153) :611-616
[9]   Randomised trial of old and new antihypertensive drugs in elderly patients:: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study [J].
Hansson, L ;
Lindholm, LH ;
Ekbom, T ;
Dahlöf, B ;
Lanke, J ;
Scherstén, B ;
Wester, PO ;
Hedner, T ;
de Faire, U .
LANCET, 1999, 354 (9192) :1751-1756
[10]  
HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541